Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
Moleculin Biotech released a CEO Corner segment focusing on the differentiated safety profile of its lead drug candidate, Annamycin, designed to avoid cardiotoxicity common with traditional anthracyclines. The company is conducting a pivotal Phase 3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML), positioning Annamycin as a pr…